Meridian launches Epstein-Barr tests:
This article was originally published in Clinica
Meridian Bioscience has launched two tests for Epstein-Barr virus (EBV), TRU EBV-M and TRU EBV-G, in Europe, including Scandinavia. The tests, which were approved there in late March, are the first on the market using recombinant antigen technology to detect immunoglobulin (Ig)M and IgG antibodies specific to EBV, the Cincinnati, Ohio-based firm claimed. EBV causes infectious mononucleosis, or glandular fever, and current glandular fever diagnostics rely primarily on the patient's symptoms and non-specific antibody testing, Meridian said. CEO Jack Kraeutler said the firm would monitor the products' success in Europe before deciding whether to file them in the US.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.